Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6626-6636

  Yan, Pearlly S ^a   Venkataramu, Chinnambally ^d   Ibrahim, Ashraf ^e   Liu, Joseph C ^a   Shen, Rulong Z ^c   Diaz, Nils M ^d   Centeno, Barbara ^d   Weber, Frank ^g   Leu, Yu Wei ^f   Shapiro, Charles L ^b   Eng, Charis ^g   Yeatman, Timothy J ^d   Huang, Tim H M ^a,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ALLELIC IMBALANCE; ARTICLE; BREAST; BREAST TUMOR; CANCER RISK; CHROMOSOME 3P; CONTROLLED STUDY; DNA FLANKING REGION; DNA HYBRIDIZATION; DNA METHYLATION; DNA MICROARRAY; DNA SCREENING; EPIGENETICS; GENE MAPPING; GENETIC ANALYSIS; GEOGRAPHIC PATHOLOGY; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION;

ALLELIC IMBALANCE; BREAST NEOPLASMS; CARCINOMA; CHROMOSOMES, HUMAN, PAIR 3; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; HUMANS; LOSS OF HETEROZYGOSITY; MAMMARY GLANDS, HUMAN; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGIONS (GENETICS); TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 33845333815     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0467     Document Type: Article

References (46)

1. Kaplan J, Giron G, Tartter PI, Bleiweiss IJ, Estabrook A, Smith SR. Breast conservation in patients with multiple ipsilateral synchronous cancers. J Am Coll Surg 2003;197:726-9.
2. Fredriksson I, Liljegren G, Palm-Sjovall M, et al. Risk factors for local recurrence after breast-conserving surgery. Br J Surg 2003;90:1093-102.
3. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996;274:2057-9.
4. Ellsworth DL, Ellsworth RE, Love B, et al. Outer breast quadrants demonstrate increased levels of genomic instability. Ann Surg Oncol 2004;11:861-8.
5. Li Z, Moore DH, Meng ZH, Ljung BM, Gray JW, Dairkee SH. Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients. Cancer Res 2002;62:1000-3.
6. Ellsworth RE, Ellsworth DL, Neatrour DM, et al. Allelic imbalance in primary breast carcinomas and metastatic tumors of the axillary lymph nodes. Mol Cancer Res 2005;3:71-7.
7. Larson PS, de las Morenas A, Bennett SR, Cupples LA, Rosenberg CL. Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol 2002;161:283-90.
8. Larson PS, de las Morenas A, Cupples LA, Huang K, Rosenberg CL. Genetically abnormal clones in histologically normal breast tissue. Am J Pathol 1998;152:1591-8.
9. Lynch ED, Ostermeyer EA, Lee MK, et al. Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis. Am J Hum Genet 1997;61:1254-60.
10. Widschwendter M, Berger J, Daxenbichler G, et al. Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 1997;57:4158-61.
11. Yan PS, Shi H, Rahmatpanah F, et al. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res 2003;63:6178-86.
12. Lewis CM, Cler LR, Bu DW, et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005;11:166-72.
13. Holst CR, Nuovo GJ, Esteller M, et al. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 2003;63:1596-601.
14. Bird A. DNA methylation de novo. Science 1999;286:2287-8.
15. Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett 2003;190:125-33.
16. Yan PS, Chen CM, Shi H, et al. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 2001;61:8375-80.
17. Lehmann U, Berg-Ribbe I, Wingen LU, et al. Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res 2005;11:3654-60.
18. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001;20:3348-53.
19. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-6.
20. Yan PS, Wei SH, Huang TH. Methylation-specific oligonucleotide microarray. Methods Mol Biol 2004;287:251-60.
21. Gitan RS, Shi H, Chen CM, Yan PS, Huang TH. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res 2002;12:158-64.
22. Yan PS, Wei SH, Huang TH. Differential methylation hybridization using CpG island arrays. Methods Mol Biol 2002;200:87-100.
23. Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999;8:459-70.
24. Aldred MA, Ginn-Pease ME, Morrison CD, et al. Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 2003;63:2864-71.
25. Boehm D, Herold S, Kuechler A, Liehr T, Laccone F. Rapid detection of subtelomeric deletion/duplication by novel real-time quantitative PCR using SYBR-green dye. Hum Mutat 2004;23:368-78.
26. Marsh DJ, Dahia PL, Coulon V, et al. Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer 1998;21:61-9.
27. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet 2001;10:1907-13.
28. Heisler LE, Torti D, Boutros PC, et al. CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res 2005;33:2952-61.
29. Nouzova M, Holtan N, Oshiro MM, et al. Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. J Pharmacol Exp Ther 2004;311:968-81.
30. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
31. Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD. Genomic instability in histologically normal breast tissues: implications for carcinogenesis. Lancet Oncol 2004;5:753-8.
32. Ellsworth DL, Ellsworth RE, Love B, et al. Genomic patterns of allelic imbalance in disease free tissue adjacent to primary breast carcinomas. Breast Cancer Res Treat 2004;88:131-9.
33. Pieper U, Groll DH, Wunsch S, et al. The GTP-dependent restriction enzyme McrBC from Escherichia coli forms high-molecular mass complexes with DNA and produces a cleavage pattern with a characteristic 10-base pair repeat. Biochemistry 2002;41:5245-54.
34. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R. Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 2005;25:3923-33.
35. Ballestar E, Esteller M. The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications. Prog Mol Subcell Biol 2005;38:169-81.
36. Santoro R, Grummt I. Epigenetic mechanism of rRNA gene silencing: temporal order of NoRC-mediated histone modification, chromatin remodeling, and DNA methylation. Mol Cell Biol 2005;25:2539-46.
37. Wade PA. Switching off methylated DNA. Nat Genet 2005;37:212-3.
38. Leu YW, Yan PS, Fan M, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004;64:8184-92.
39. Thakur N, Kanduri M, Holmgren C, Mukhopadhyay R, Kanduri C. Bidirectional silencing and DNA methylation-sensitive methylation-spreading properties of the Kcnq1 imprinting control region map to the same regions. J Biol Chem 2003;278:9514-9.
40. Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene 2002;21:5388-93.
41. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-8.
42. Maekita T, Nakazawa K, Mihara M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006;12:989-95.
43. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005;10:370-81.
44. Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 2005;205:172-80.
45. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005;26:1481-7.
46. Gaston SM, Soares MA, Siddiqui MM, et al. Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule. Nat Med 2005;11:95-101.